On November 17, Tyruko (reference product, Tysabri) became available to treat relapsing forms of multiple sclerosis (MS), in addition to Crohn’s disease. This agent is the first biosimilar to treat MS in the United States. Manufactured by Polpharma Biologics and commercialized by Sandoz, Tyruko was approved by the FDA in August 2023, but its launch … Continue reading Sandoz Announces the Launch of Tyruko, the First Biosimilar for the Treatment of Multiple Sclerosis